Fortis and Agilus expand rapid genomic testing capabilities with launch of Second Genexus System

New Delhi: In a significant advancement towards precision medicine, Fortis Memorial Research Institute (FMRI), Gurugram, in collaboration with Agilus Diagnostics, has launched its second Genexus system, further strengthening the nation’s fastest and most scalable rapid genomic testing program.

The Genexus platform enables Next-Generation Sequencing (NGS) with an unparalleled turnaround time – delivering crucial results such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and MRD testing within 5 days. These timeframes significantly outperform traditional diagnostic methods, which often take weeks and offer limited insight into genetic complexity.

“With the addition of the second Genexus system, we can now scale our rapid NGS workflow for AML and other hematologic malignancies across more patients and regions,” said Dr. Rahul Bhargava, Principal Director and Chief – Haematology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. “Genomics is not the future anymore – it is the present. Every mutation tells a story. With faster and deeper insights, we’re not only making better treatment decisions but also giving our patients a genuine shot at survival and long-term remission.”

Thanks to the rapid NGS (Next-Generation Sequencing) program at Fortis and Agilus, doctors can now uncover the genetic reasons behind a person’s cancer in just a few days – something that used to take weeks. This breakthrough has led to real and meaningful improvements in patient care:

With Genexus 2.0, Fortis and Agilus are leading the charge in making precision cancer care faster, smarter, and more accessible for every patient.

Dr. Anand K, MD & CEO, Agilus Diagnostics, said, “With the second Genexus system in place, we are better positioned to democratize access to advanced molecular diagnostics, delivering not just results, but truly actionable insights in record time. This marks a critical step in bringing personalized medicine closer to every Indian cancer patient.”

Powered by Fortis’ clinical excellence and Agilus’ national laboratory infrastructure, this collaboration brings together haematologists, oncologists, molecular pathologists, and bioinformaticians under one umbrella. The goal: to ensure that no patient waits unnecessarily for life-saving genomic results.